Cowen Prime Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$176K Sell
1,304
-1,200
-48% -$176K 0.06% 91
2023
Q1
$378K Buy
2,504
+50
+2% +$7.64K 0.15% 64
2022
Q4
$397K Buy
2,454
+2,150
+707% +$330K 0.16% 61
2022
Q3
$41K Hold
304
0.02% 115
2022
Q2
$47K Hold
304
0.03% 117
2022
Q1
$49K Hold
304
0.02% 125
2021
Q4
$41K Hold
304
0.01% 126
2021
Q3
$33K Hold
304
0.01% 129
2021
Q2
$34K Hold
304
0.01% 123
2021
Q1
$33K Hold
304
0.01% 124
2020
Q4
$33K Hold
304
0.01% 124
2020
Q3
$27K Hold
304
0.01% 133
2020
Q2
$47K Buy
304
+4
+1% +$352 0.03% 117
2020
Q1
$23K Hold
300
0.01% 132
2019
Q4
$27K Hold
300
0.01% 127
2019
Q3
$23K Hold
300
0.01% 129
2019
Q2
$22K Hold
300
0.01% 136
2019
Q1
$24K Sell
300
-500
-63% -$40.9K 0.01% 136
2018
Q4
$74K Hold
800
0.04% 106
2018
Q3
$76K Hold
800
0.04% 127
2018
Q2
$74K Buy
800
+200
+33% +$19.5K 0.04% 122
2018
Q1
$57K Sell
600
-200
-25% -$22K 0.03% 134
2017
Q4
$77K Hold
800
0.04% 127
2017
Q3
$71K Sell
800
-28,485
-97% -$2.17M 0.03% 119
2017
Q2
$2.12M Sell
29,285
-1,100
-4% -$74K 0.98% 32
2017
Q1
$1.98M Sell
30,385
-19,965
-40% -$1.26M 1.02% 31
2016
Q4
$3.15M Hold
50,350
1.7% 15
2016
Q3
$3.18M Sell
50,350
-6,250
-11% -$405K 1.44% 18
2016
Q2
$3.5M Sell
56,600
-4,915
-8% -$299K 1.7% 16
2016
Q1
$3.51M Sell
61,515
-1,035
-2% -$57.7K 1.63% 17
2015
Q4
$3.71M Buy
62,550
+900
+1% +$51.8K 1.64% 19
2015
Q3
$3.35M Buy
61,650
+7,229
+13% +$471K 1.57% 19
2015
Q2
$3.66M Sell
54,421
-461
-0.8% -$30.1K 1.43% 17
2015
Q1
$3.21M Buy
54,882
+7,578
+16% +$458K 1.32% 20
2014
Q4
$3.1M Buy
47,304
+7,604
+19% +$479K 1.22% 21
2014
Q3
$2.29M Buy
39,700
+34,405
+650% +$1.91M 1% 22
2014
Q2
$299K Buy
5,295
+5
+0.1% +$262 0.12% 74
2014
Q1
$272K Buy
5,290
+4
+0.1% +$202 0.1% 81
2013
Q4
$279K Buy
5,286
+5
+0.1% +$246 0.11% 84
2013
Q3
$237K Buy
5,281
+90
+2% +$3.99K 0.09% 104
2013
Q2
$216K Buy
+5,191
New +$227K 0.09% 104

Other funds holding ABBV

Cowen Prime Advisors's ABBV Position: Q2 2023 in Review

Cowen Prime Advisors reduced its AbbVie (ABBV) stake by 48% in Q2 2023, selling an estimated $176K and leaving 1,304 shares worth $176K. The position accounts for 0.06% of the portfolio, ranked #91.

Cowen Prime Advisors first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $3.71M in Q4 2015. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

  • Cowen Prime Advisors held 1,304 shares of AbbVie worth $176K as of Q2 2023.
  • Cowen Prime Advisors sold 1,200 AbbVie shares in Q2 2023, an estimated $176K.
  • AbbVie made up 0.06% of Cowen Prime Advisors's portfolio in Q2 2023, its #91 holding.
  • Cowen Prime Advisors first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
  • Cowen Prime Advisors's AbbVie position peaked at $3.71M in Q4 2015.
  • 3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.